Clinical Trials Logo

Hematologic Neoplasms clinical trials

View clinical trials related to Hematologic Neoplasms.

Filter by:

NCT ID: NCT04310592 Recruiting - Leukemia Clinical Trials

Natural Killer Cell (CYNK-001) Infusions in Adults With AML

CYNK001AML01
Start date: March 12, 2020
Phase: Phase 1
Study type: Interventional

This study will find the maximum tolerated dose or the maximum planned dose of CYNK-001 which contains natural killer (NK) cells derived from human placental CD34+ cells and culture-expanded. CYNK-001 cells will be given after lymphodepleting chemotherapy. The safety of this treatment will be evaluated, and researchers want to learn if NK cells will help in treating acute myeloid leukemia.

NCT ID: NCT04305249 Recruiting - Solid Tumor Clinical Trials

Safety and Preliminary Efficacy of ATG-017 Monotherapy or Combination Therapy With Nivolumab in Advanced Solid Tumors and Hematological Malignancies

ERASER
Start date: August 15, 2020
Phase: Phase 1
Study type: Interventional

This is a Phase I, multi-center, open-label study of ATG-017 administered orally, alone or in combination with nivolumab in patients with advanced solid tumors and hematological malignancies. The study is composed of two modules: ATG-017 monotherapy (Module A) and ATG-017 in combination with nivolumab (Module B). Both Modules A and B will include Dose Escalation Phase and Dose Expansion Phase.

NCT ID: NCT04298892 Recruiting - Clinical trials for Haematological Malignancy

Integrated Multiomics and Multilevel Characterization of Haematological Disorders and Malignancies

INTHEMA
Start date: January 7, 2020
Phase:
Study type: Observational [Patient Registry]

Exploratory multicenter, non-interventional, translational, retrospective and prospective study. All patients with a diagnosis of hematologic disorder or malignancy for whom biological samples and clinical data are available may be included in this study, after obtaining informed consent

NCT ID: NCT04290000 Recruiting - Clinical trials for Lymphoma and Acute Lymphoblastic Leukemia

Collection of Biological Samples From Patients Treated With CAR-T Cells for Hematological Malignancies

CAR-T BANK
Start date: March 27, 2020
Phase:
Study type: Observational

Development of CAR-T cell against CD19 B lymphoma and Acute Lymphoblastic Leukemia leaded to 2 authorized medication: Yescarta and Kymriah. Despite impressive outcomes in 3 phase II studies, never met in relapsed or refractory diseases, half of the patients don't respond to this treatment.This can be explained by a low expansion, functional alteration or short persistence of infused cells. Determination of reasons for treatment failure is the first step for optimization of this therapeutics. This project aims to bank blood samples from a cohort of patients treated with CAR-T cell for hematological malignancies in Montpellier University Hospital. Clinical data related to samples will be collected. This samples will be used to determine factors influencing efficacy of CAR-T cells treatments.

NCT ID: NCT04283097 Recruiting - Clinical trials for Hematological Malignancies

Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects

Start date: September 13, 2021
Phase: Phase 1
Study type: Interventional

This is a phase 1, multicenter, open-label, multiple-ascending dose study to evaluate the safety, pharmacokinetics and clinical activity of KPG-818 in subjects with hematological malignancies. Approximately 30 patients will be enrolled for dose escalation of 4 dose levels. Indication: Hematological malignancies (multiple myeloma [MM], mantle cell lymphoma [MCL], diffuse large B-cell lymphoma [DLBCL], adult T-cell leukemia-lymphoma [ATL], and indolent non Hodgkin lymphomas such as follicular lymphoma [FL] and chronic lymphocytic leukemia [CLL]/small lymphocytic lymphoma [SLL]).

NCT ID: NCT04283006 Recruiting - Clinical trials for Relapsed and Refractory

A Study of CD20/CD22 Targeted CAR T-cell Therapy for Relapsed or Refractory Lymphoid Malignancies

Start date: May 23, 2018
Phase: Early Phase 1
Study type: Interventional

A Study of CD20/CD22 Targeted CAR T-cell Therapy for Relapsed or Refractory Lymphoid Malignancies.

NCT ID: NCT04264078 Recruiting - T-cell Lymphoma Clinical Trials

Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic Malignancies

Start date: March 1, 2021
Phase: Early Phase 1
Study type: Interventional

The prognosis of patients with relapsed and/or refractory T-cell hematologic malignancies is poor due to lacking sufficient treatment.Anti-CD(cluster of differentiation antigen)19 CAR(chimeric antigen receptor)-T cell therapies are efficient for patients with B-cell hematologic malignancies. As for T-cell hematologic malignancies, CD7 is a promising target expressed on most malignant T cells. The outcome of CD-7 CAR-T cell therapy pre-clinical experiments is cheerful.however, how to select the functional T cells from the malignant T cells is a challenge. In addition to this, auto-CAR-T cell therapy is not affordable for the majority of patients. Using T cells aphesis from healthy donors edited to avoid rejection of the host as the material of anti-CD7 universal CAR-T cells could be accessible and affordable, which is adapted for patients with CD7+ relapsed and/or refractory T/NK-cell hematologic malignancies.

NCT ID: NCT04263857 Recruiting - Clinical trials for Hematologic Malignancies

Register of Blood Stem Cell Transplantation

REBB3M
Start date: November 1, 2017
Phase:
Study type: Observational [Patient Registry]

Register of patients with blood stem cell transplantations (autologous, allogen).

NCT ID: NCT04237623 Recruiting - Clinical trials for Transplant-Related Hematologic Malignancy

GM-CSF With Post-Transplant Cyclophosphamide

Start date: May 18, 2020
Phase: Phase 2
Study type: Interventional

Given the increased number of HLA-mismatched haploidentical transplantation with post-transplant cyclophosphamide performed each year and the high risk of infectious complications associated with this type of transplant, the investigators suggest that GM-CSF administration post-infusion of T-replete haploidentical stem cells and post-transplant cyclophosphamide can yield similar count recovery rates to G-CSF with a potential of lowering risk of infectious complications.

NCT ID: NCT04227015 Recruiting - Clinical trials for Acute Lymphoblastic Leukemia

A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy

Start date: January 8, 2020
Phase: Early Phase 1
Study type: Interventional

A study of CTA101 UCAR-T cell injection in patients with relapsed or refractory CD19+ B-line hematological malignancy